Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions
Omnipod ® Horizon ™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 24, 2018-- Insulet Corporation  (NASDAQ:PODD) (Insulet or the Company), the leader in  tubeless insulin pump technology with its Omnipod ®  Insulin Management
View HTML
Toggle Summary Insulet to Unveil New Omnipod® DASH™ System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions
DASH System Features Sleek, Color Touch-Screen Handheld Personal Diabetes Manager, Bluetooth-Enabled, Waterproof 1 , Tubeless Pump BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 19, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in  tubeless insulin pump technology with
View HTML
Toggle Summary Insulet’s Omnipod® DASH™ Insulin Management System Receives FDA 510(k) Clearance
DASH System Features Sleek, Color Touch-Screen Handheld Personal Diabetes Manager, Bluetooth-Enabled, Waterproof 1 , Tubeless Pump and Suite of User-Friendly Mobile Applications No-Cost Personal Diabetes Manager with Purchase of Pods BILLERICA, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conference
BILLERICA, Mass. --(BUSINESS WIRE)--May 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the William Blair & Company 38 th Annual Growth Stock
View HTML
Toggle Summary Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations
Increases Full Year 2018 Expected Revenue Growth to 22% to 25% on Strength in Global Omnipod; Introduces Second Quarter Expected Revenue Growth of 18% to 22% BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless
View HTML
Toggle Summary Insulet Achieves Key Milestones to Support its Transition to Direct Operations in Europe on July 1, 2018
High-Caliber Team in Place Throughout Key Geographies Partnerships Established with Experienced European Companies for Customer Care and Logistics BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin
View HTML
Toggle Summary Insulet Establishes Two Significant Commercial Partnerships to Support its European Expansion
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 1, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it has entered into partnerships with two
View HTML
Toggle Summary Insulet to Announce First Quarter 2018 Financial Results on May 3, 2018
BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 5, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the first quarter of 2018 on May
View HTML
Toggle Summary Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses
Strong Presence at National Professional Diabetes Congresses in the UK , France and Germany Demonstrates Insulet’s Commitment to the European Diabetes Community BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless
View HTML
Toggle Summary Insulet Expands Access to Omnipod® as an In-Network Provider with UnitedHealthcare
Insulet Expands Access to Omnipod® as an In-Network Provider with UnitedHealthcare – For more information, please see the following link .
View HTML
Toggle Summary Insulet Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at three upcoming investor conferences: This press release
View HTML
Toggle Summary Insulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations
Full Year 2017 Revenue of $463.8 Million , Up 26%, and Gross Margin Up 230 Basis Points Full Year 2018 Expected Revenue Growth of 21% to 25% BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump
View HTML
Toggle Summary Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon™ Hybrid Closed-Loop System
Significant Presence at ATTD Congress Demonstrates Insulet’s Future Commitment to the Diabetes Community in Europe Studies Show Exceptional Potential for the Omnipod Horizon System to Maintain Stable Blood Glucose Levels after Specific Meal and Exercise Challenges BILLERICA, Mass.
View HTML
Toggle Summary Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018
BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year
View HTML
Toggle Summary Medicare Part D (Prescription Drug) Plans May Now Cover Omnipod®
Significantly Expands Access to Omnipod and Provides a Pathway to Broader Medicaid Coverage BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ®  Insulin Management System
View HTML